<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="6fdafb53-4fe1-449d-98cd-aaa175da52fd"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title mediaType="text/x-hl7-title+xml">
      <content styleCode="bold">These highlights do not include all the information needed to use TEGSEDI<sup>Â®</sup> safely and effectively.  See full prescribing information for TEGSEDI.
			<br/>
         <br/>TEGSEDI (inotersen) injection, for subcutaneous use
			<br/>Initial U.S. Approval: 2018</content>
   </title>
   <effectiveTime value="20240125"/>
   <setId root="8513207e-b55f-417b-9473-af785146a543"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="079911419" root="1.3.6.1.4.1.519.1"/>
            <name>Akcea Therapeutics, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ab8f637a-69d1-47c2-bf7e-817df3f693d0"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20190520"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72126-007" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Tegsedi</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>inotersen</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="284" unit="mg"/>
                              <denominator value="1.5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="950736UC77" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>INOTERSEN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0IEO0F56LV" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INOTERSEN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72126-007-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="4" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="72126-007-01" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20181005"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA211172" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20181005"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText>colourless to pale yellow solution</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="recentchanges">
               <id root="bf20004e-42c7-43d4-9dea-c9d914becb8b"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="600" styleCode="Noautorules">
                           <col width="90%" align="left"/>
                           <col width="10%" align="left"/>
                           <tbody>
                              <tr valign="bottom">
                                 <td>Dosage and Administration (<linkHtml href="#s_0204">2.4</linkHtml>)</td>
                                 <td>1/2024</td>
                              </tr>
                              <tr valign="bottom">
                                 <td>Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml>, <linkHtml href="#s_0506">5.6</linkHtml>)</td>
                                 <td>1/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s_bw">
               <id root="9e381023-a292-47cb-863f-b534c4477c77"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title mediaType="text/x-hl7-title+xml">WARNING: THROMBOCYTOPENIA AND GLOMERULONEPHRITIS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold underline">Thrombocytopenia</content>
                  </paragraph>
                  <paragraph>TEGSEDI causes reductions in platelet count that may result in sudden and unpredictable thrombocytopenia, which can be life-threatening. One clinical trial patient died from intracranial hemorrhage.</paragraph>
                  <paragraph>TEGSEDI is contraindicated in patients with a platelet count below 100 x 10<sup>9</sup>/L <content styleCode="italics">[see Contraindications (<linkHtml href="#s_0400">4</linkHtml>) and Warnings and Precautions (<linkHtml href="#s_0502">5.2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>Prior to starting TEGSEDI, obtain a platelet count <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s_0203">2.3</linkHtml>)].</content> During treatment, monitor platelet counts weekly if values are 75 x 10<sup>9</sup>/L or greater, and more frequently if values are less than 75 x 10<sup>9</sup>/L  <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s_0204">2.4</linkHtml>) and Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>If a patient develops signs or symptoms of thrombocytopenia, obtain a platelet count as soon as possible. The patient should not receive additional TEGSEDI unless a platelet count is  determined to be interpretable and acceptable by a medical professional <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>Following discontinuation of treatment for any reason, continue to monitor platelet count for 8 weeks, or longer if platelet counts are less than 100 x 10<sup>9</sup>/L, to verify that platelet counts remain above 75 x 10<sup>9</sup>/L  <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s_0204">2.4</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold underline">Glomerulonephritis</content>
                  </paragraph>
                  <paragraph>TEGSEDI can cause glomerulonephritis that may require immunosuppressive treatment and may result in dialysis-dependent renal failure. One clinical trial patient who developed glomerulonephritis and did not receive immunosuppressive treatment remained dialysis-dependent. In clinical trials, cases of glomerulonephritis were accompanied by nephrotic syndrome, which can have manifestations of edema, hypercoagulability with venous or arterial thrombosis, and increased susceptibility to infection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0502">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>TEGSEDI should generally not be initiated in patients with urinary protein to creatinine ratio (UPCR) of 1000 mg/g or higher <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s_0204">2.4</linkHtml>) and Warnings and Precautions (<linkHtml href="#s_0502">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>Prior to starting TEGSEDI, measure the serum creatinine, estimated glomerular filtration rate (eGFR), urine protein to creatinine ratio (UPCR), and perform a urinalysis <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s_0203">2.3</linkHtml>)]</content>. During treatment, monitor serum creatinine, eGFR urinalysis, and UPCR every two  weeks. TEGSEDI should not be given to patients who develop a UPCR of 1000 mg/g or higher, or eGFR below 45 mL/minute/1.73 m<sup>2</sup>, pending further evaluation of the cause. </paragraph>
                  <paragraph>If a dose is held, once eGFR increases to â¥45 mL/minute/1.73 m<sup>2</sup>, UPCR decreases to below 1000 mg/g, or the underlying cause of the decline in renal function is corrected, weekly dosing may be reinitiated.  In patients with UPCR of 2000 mg/g or higher, perform further evaluation for acute glomerulonephritis, as clinically indicated. If acute glomerulonephritis is confirmed, TEGSEDI should be permanently discontinued <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s_0204">2.4</linkHtml>) and Warnings and Precautions (<linkHtml href="#s_0502">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold underline">TEGSEDI REMS Program</content>
                  </paragraph>
                  <paragraph>Because of the risks of serious bleeding caused by severe thrombocytopenia and because of glomerulonephritis, both of which require frequent monitoring, TEGSEDI is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) called the TEGSEDI REMS Program <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0503">5.3</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20200902"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: THROMBOCYTOPENIA AND GLOMERULONEPHRITIS </paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold underline">Thrombocytopenia</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">TEGSEDI causes reductions in platelet count that may result in sudden and unpredictable thrombocytopenia, which can be  life-threatening. (<linkHtml href="#s_0501">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Testing prior to treatment and monitoring during treatment is required (<linkHtml href="#s_0203">2.3</linkHtml>, <linkHtml href="#s_0204">2.4</linkHtml>, <linkHtml href="#s_0501">5.1</linkHtml>)</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold underline">Glomerulonephritis</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">TEGSEDI can cause glomerulonephritis that may require immunosuppressive treatment and may result in dialysis-dependent renal failure. (<linkHtml href="#s_0502">5.2</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Testing prior to treatment and monitoring during treatment is required (<linkHtml href="#s_0203">2.3</linkHtml>, <linkHtml href="#s_0204">2.4</linkHtml>, <linkHtml href="#s_0502">5.2</linkHtml>)</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">TEGSEDI is available only through a restricted distribution program called the TEGSEDI REMS Program (<linkHtml href="#s_0503">5.3</linkHtml>).</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s_0100">
               <id root="00e3707a-11e1-4659-878b-2ad9e3a6d9af"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title mediaType="text/x-hl7-title+xml">1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.</paragraph>
               </text>
               <effectiveTime value="20190515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>TEGSEDI is a transthyretin-directed antisense oligonucleotide indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults (<linkHtml href="#s_0100">1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s_0200">
               <id root="eef778b7-bb65-46b8-9f4a-a90fa9b61c8b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title mediaType="text/x-hl7-title+xml">2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dosage is 284 mg administered by subcutaneous injection once weekly. (<linkHtml href="#s_0201">2.1</linkHtml>)</item>
                           <item>Laboratory tests must be measured prior to treatment, continue to be monitored after treatment initiation, and for 8 weeks following discontinuation of treatment, as directed. (<linkHtml href="#s_0203">2.3</linkHtml>, <linkHtml href="#s_0204">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s_0201">
                     <id root="23003fb7-f3a6-4822-b225-6594c2bf5582"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">2.1 Dosing Information</title>
                     <text>
                        <paragraph>The recommended dose of TEGSEDI is 284 mg injected subcutaneously once weekly.</paragraph>
                        <paragraph>For consistency of dosing, patients should be instructed to give the injection on the same day every week.</paragraph>
                        <paragraph>If a dose is missed, patients should be instructed to take the missed dose as soon as possible, unless the next scheduled dose is within 2 days. In this situation, the patient should be directed to skip the missed dose and take the next scheduled dose on the scheduled day.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0202">
                     <id root="6c1301a7-5f81-4b48-a6e4-bced2526067c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">2.2 Administration</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>TEGSEDI is intended for subcutaneous use only.</item>
                           <item>The first injection administered by the patient or caregiver should be performed under the guidance of an appropriately qualified healthcare professional. Patients and/or caregivers should be trained in the subcutaneous administration of TEGSEDI in accordance with the Instructions for Use.</item>
                           <item>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit <content styleCode="italics">[see How Supplied/Storage and Handling (<linkHtml href="#s_1600">16</linkHtml>)].</content>
                           </item>
                           <item>Sites for injection include the abdomen, upper thigh region, or outer area of the upper arm. It is important to rotate sites for injection.
										<paragraph>Â Â Â <caption>-</caption> If injected in the upper arm, the injection should be administered by a person other than the patient.</paragraph>
                              <paragraph>Â Â Â <caption>-</caption> Injection should be avoided at the waistline and other sites where pressure or rubbing from clothing may occur.</paragraph>
                              <paragraph>Â Â Â <caption>-</caption> TEGSEDI should not be injected into areas of skin disease or injury.</paragraph>
                              <paragraph>Â Â Â <caption>-</caption> Tattoos and scars should also be avoided.</paragraph>
                           </item>
                           <item>TEGSEDI prefilled syringe should be allowed to reach room temperature prior to injection.
										<paragraph>Â Â Â <caption>-</caption> Remove from refrigerated storage at least 30 minutes prior to use.</paragraph>
                              <paragraph>Â Â Â <caption>-</caption> Other warming methods should not be used.</paragraph>
                           </item>
                           <item>Use each prefilled syringe only once.</item>
                        </list>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0203">
                     <id root="3bcd56b2-1606-4a07-8bf3-725c874c3010"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">2.3 Assessment Prior to Initiating TEGSEDI</title>
                     <text>
                        <paragraph>Measure platelet count, serum creatinine, estimated glomerular filtration rate (eGFR), urine protein to creatinine ratio (UPCR), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, and perform urinalysis prior to treatment with TEGSEDI and as directed following treatment initiation <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s_0204">2.4</linkHtml>) and Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml> and <linkHtml href="#s_0502">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0204">
                     <id root="1778e298-de0a-4926-94df-331e06a8bb8f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">2.4	Laboratory Testing and Monitoring  to Assess Safety after Initiating TEGSEDI</title>
                     <text>
                        <paragraph>Monitor platelet count, serum creatinine, estimated glomerular filtration rate (eGFR), urinalysis, urine protein to creatinine ratio (UPCR), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin during treatment with TEGSEDI, and for 8 weeks following discontinuation of treatment.</paragraph>
                        <paragraph styleCode="underline">Platelet Count</paragraph>
                        <paragraph>Do not initiate TEGSEDI in patients with a platelet count less than 100 x 10<sup>9</sup>/L. Monitor platelet count during the entire course of treatment with Tegsedi and for 8 weeks following discontinuation of treatment. Recommendations for platelet monitoring frequency and TEGSEDI dosing are specified in <linkHtml href="#table1">Table 1</linkHtml>. If a patient develops signs or symptoms of thrombocytopenia, obtain a platelet count as soon as possible, and hold dosing until platelet count is confirmed. Recheck the platelet count as soon as possible if a platelet measurement is uninterpretable (e.g., clumped sample) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0508">5.8</linkHtml>]</content>.</paragraph>
                        <table styleCode="Noautorules" ID="table1" width="750">
                           <caption>Table 1:	TEGSEDI Monitoring and Treatment Recommendations for Platelet Count</caption>
                           <col width="30%" align="left"/>
                           <col width="35%" align="left"/>
                           <col width="35%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left">
                                    <sup>*</sup> It is strongly recommended that, unless the patient has a medical contraindication to receiving glucocorticoids, the patient receive glucocorticoid therapy to reverse the platelet decline <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml>)]</content>.<br/>
												# Additional risk factors for bleeding include age &gt;60 years, receiving anticoagulant or antiplatelet medicinal products, or prior history of major bleeding events.<br/>
												â Patients who discontinue therapy with TEGSEDI because of platelet counts below 25 x10<sup>9</sup>/L should not reinitiate therapy.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="left">Platelet count (x10<sup>9</sup>/L)</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="left">Monitoring Frequency</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="left">Dosing</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule" valign="top" align="left">At least 100</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">Weekly</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">Continue to dose weekly.</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule" valign="top" align="left">At least 75 to less than 100</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">Weekly</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">Stop treatment. Do not restart unless platelet count is greater than 100.</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule" valign="top" align="left">At least 50 to less than 75</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">Twice weekly until 3 successive values above 75; then weekly monitoring.  </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">Stop treatment. Do not restart TEGSEDI in patients with thrombocytopenia, unless there have been 3 successive values above 100 and the benefit of TEGSEDI outweighs the risk of thrombocytopenia and potential bleeding.</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="left">At least 25 to less than 50<sup>*</sup>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <paragraph>Twice weekly until 3 successive values above 75; then weekly monitoring.</paragraph>
                                    <paragraph>Consider more frequent monitoring if additional risk factors for bleeding are present.<sup>#</sup>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <paragraph>Stop treatment. Do not restart TEGSEDI in patients with thrombocytopenia, unless there have been 3 successive values above 100 and the benefit of TEGSEDI outweighs the risk of thrombocytopenia and potential bleeding.</paragraph>
                                    <paragraph>Corticosteroids recommended.</paragraph>
                                    <paragraph>Consider discontinuation of any antiplatelet agents or anticoagulants.</paragraph>
                                 </td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="left">Less than 25<sup>*â </sup>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">Daily until 2 successive values above 25. Then monitor twice weekly until 3 successive values above 75. Then weekly monitoring until stable.</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <paragraph>Stop TEGSEDI.</paragraph>
                                    <paragraph>Corticosteroids recommended.</paragraph>
                                    <paragraph>Consider discontinuation of any antiplatelet agents or anticoagulants.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph styleCode="underline">Renal Monitoring</paragraph>
                        <paragraph>TEGSEDI should generally not be initiated in patients with a urine protein to creatinine ratio (UPCR) of 1000 mg/g or higher. Monitor serum creatinine, estimated glomerular filtration rate (eGFR), urinalysis, and UPCR every 2 weeks during treatment with TEGSEDI. Hold TEGSEDI in patients who develop a UPCR of 1000 mg/g or higher, or estimated glomerular filtration rate (eGFR) below 45 mL/minute/1.73 m<sup>2</sup>, pending further evaluation of the cause.</paragraph>
                        <paragraph>If a dose is held, once eGFR increases to â¥45 mL/minute/1.73 m<sup>2</sup>, UPCR decreases to below 1000 mg/g, or the underlying cause of the decline in renal function is corrected, weekly dosing may be reinitiated. In the case of UPCR of 2000 mg/g or higher, perform further evaluation for acute glomerulonephritis, as clinically indicated. If acute glomerulonephritis is confirmed, TEGSEDI should be permanently discontinued.</paragraph>
                        <paragraph styleCode="underline">Liver Tests</paragraph>
                        <paragraph>Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin monthly during treatment with TEGSEDI; monitor monthly for patients who have received a liver transplant <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0506">5.6</linkHtml>)]</content>. TEGSEDI should be discontinued in patients suspected of developing liver injury induced by TEGSEDI <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0506">5.6</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_0300">
               <id root="8816d1a3-a848-4d2b-bc58-467a1298f84f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 284 mg/1.5 mL clear, colorless to pale yellow solution in a single-dose prefilled syringe.</paragraph>
               </text>
               <effectiveTime value="20181015"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 284 mg/ 1.5 mL  in a single-dose prefilled syringe (<linkHtml href="#s_0300">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s_0400">
               <id root="b8a9fd3c-631c-4f55-80cb-323c1262556e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>TEGSEDI is contraindicated in patients with:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Platelet count below 100 x 10<sup>9</sup>/L <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml>)]</content>
                     </item>
                     <item>History of acute glomerulonephritis caused by TEGSEDI <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0502">5.2</linkHtml>)]</content>
                     </item>
                     <item>History of a hypersensitivity reaction to TEGSEDI <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0507">5.7</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20181015"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Platelet count less than 100 x 10<sup>9</sup>/L (<linkHtml href="#s_0400">4</linkHtml>, <linkHtml href="#s_0501">5.1</linkHtml>)</item>
                           <item>History of acute glomerulonephritis caused by TEGSEDI (<linkHtml href="#s_0400">4</linkHtml>, <linkHtml href="#s_0502">5.2</linkHtml>)</item>
                           <item>Patients with a history of a hypersensitivity reaction to TEGSEDI (<linkHtml href="#s_0400">4</linkHtml>, <linkHtml href="#s_0507">5.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s_0500">
               <id root="94cf3af9-9cad-42ba-8c8a-e4097e08f0dd"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <paragraph>
                                 <content styleCode="italics">Stroke and Cervicocephalic Arterial Dissection:</content> These adverse events occurred within 2 days of first dose and with symptoms of cytokine release. Educate patients on symptoms of stroke and central nervous system arterial dissection. (<linkHtml href="#s_0504">5.4</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="italics">Inflammatory and Immune Effects</content>: Serious neurologic adverse reactions consistent with inflammatory and immune effects occurred. (<linkHtml href="#s_0505">5.5</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="italics">Liver Injury:</content> Monitor alanine amino-transferase, aspartate aminotransferase, and total bilirubin every 4 months during treatment and in case of symptoms of hepatic dysfunction. (<linkHtml href="#s_0506">5.6</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="italics">Hypersensitivity Reactions:</content> If these occur, discontinue and initiate appropriate therapy. (<linkHtml href="#s_0507">5.7</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="italics">Uninterpretable Platelet Counts: Reaction between Antiplatelet Antibodies and ethylenediaminetetra-acetic acid</content>: Platelet clumping can cause uninterpretable platelet measurement; repeat test if this is suspected. (<linkHtml href="#s_0508">5.8</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="italics">Reduced Serum Vitamin A Levels and Recommended Supplementation:</content> Supplement with the recommended daily allowance of vitamin A. Refer to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur. (<linkHtml href="#s_0509">5.9</linkHtml>)</paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s_0501">
                     <id root="97c0c0a4-c07e-46a1-b333-dfee88719871"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.1 Thrombocytopenia</title>
                     <text>
                        <paragraph>TEGSEDI causes reductions in platelet count at any time during treatment that may result in sudden and unpredictable thrombocytopenia that can be life-threatening. In Study 1 <content styleCode="italics">[see Clinical studies (<linkHtml href="#s_1400">14</linkHtml>)]</content> , platelet counts below 100 x 10<sup>9</sup>/L occurred in 25% of TEGSEDI-treated patients, compared with 2% of patients on placebo. Platelet counts below 75 x 10<sup>9</sup>/L occurred in 14% of TEGSEDI-treated patients, compared to no patient on placebo. In Study 1 and its extension study, 39% of TEGSEDI-treated patients with a baseline platelet count below 200 x10<sup>9</sup>/L had a nadir platelet count below 75 x 10<sup>9</sup>/L, compared to 6% of patients with baseline platelet counts 200 x10<sup>9</sup>/L or higher.</paragraph>
                        <paragraph>Three TEGSEDI-treated patients (3%) had sudden severe thrombocytopenia (platelet count below 25 x 10<sup>9</sup>/L), which can have potentially fatal bleeding complications, including spontaneous intracranial or intrapulmonary hemorrhage. One patient in a clinical trial experienced a fatal intracranial hemorrhage.</paragraph>
                        <paragraph>In clinical trials, all 3 patients with severe thrombocytopenia had treatment-emergent antiplatelet IgG antibodies detected shortly before or at the time of the severe thrombocytopenia. In 2 patients, platelet clumping caused uninterpretable platelet measurements that delayed the diagnosis and treatment of severe thrombocytopenia. Platelet clumping can be caused by a reaction between antiplatelet antibodies and ethylenediaminetetraacetic acid (EDTA) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0508">5.8</linkHtml>)]</content>. </paragraph>
                        <paragraph styleCode="underline">Monitoring and Dosing</paragraph>
                        <paragraph>Patients who are not able to adhere to the recommended laboratory monitoring or to the related treatment recommendations must not receive TEGSEDI. Do not initiate TEGSEDI in patients with a platelet count below 100 x 10<sup>9</sup>/L. Follow recommended monitoring and treatment recommendations for platelet count <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s_0204">2.4</linkHtml>)]</content>. If a patient develops signs or symptoms of thrombocytopenia, obtain a platelet count as soon as possible, and hold TEGSEDI dosing unless the platelet count is confirmed to be acceptable. Recheck the platelet count as soon as possible if a platelet measurement is uninterpretable (e.g., clumped sample) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0508">5.8</linkHtml>)]</content>. Hold TEGSEDI dosing until an acceptable platelet count is confirmed with an interpretable blood sample.</paragraph>
                        <paragraph styleCode="underline">Concomitant Medications with Platelet Effects</paragraph>
                        <paragraph>When considering use of TEGSEDI concomitantly with antiplatelet drugs or anticoagulants, be aware of the risk of potential bleeding from thrombocytopenia with TEGSEDI, and consider discontinuation of these drugs in patients with a platelet count less than 50 x 10<sup>9</sup>/L <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s_0701">7.1</linkHtml>)]</content>. </paragraph>
                        <paragraph styleCode="underline">Symptoms of Thrombocytopenia</paragraph>
                        <paragraph>Symptoms of thrombocytopenia can include unusual or prolonged bleeding (e.g., petechiae, easy bruising, hematoma, subconjunctival bleeding, gingival bleeding, epistaxis, hemoptysis, irregular or heavier than normal menstrual bleeding, hematemesis, hematuria, hematochezia, melena), neck stiffness or atypical severe headache. Patients and caregivers should be instructed to be vigilant for symptoms of thrombocytopenia and seek immediate medical help if they have concerns.</paragraph>
                        <paragraph styleCode="underline">Severe Thrombocytopenia: Treatment with Glucocorticoids</paragraph>
                        <paragraph>Glucocorticoid therapy is strongly recommended in patients with a platelet count below 50 x 10<sup>9</sup>/L, and in patients with suspected immune-mediated thrombocytopenia. Avoid using TEGSEDI in patients for whom glucocorticoid treatment is not advised.</paragraph>
                     </text>
                     <effectiveTime value="20240115"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0502">
                     <id root="674e0d31-a41b-4fcd-b6b5-2077bf1ffd53"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.2 Glomerulonephritis and Renal Toxicity</title>
                     <text>
                        <paragraph>TEGSEDI can cause glomerulonephritis that may result in dialysis-dependent renal failure. In Study 1 <content styleCode="italics">[see Clinical studies (<linkHtml href="#s_1400">14</linkHtml>)]</content>, glomerulonephritis occurred in three (3%) TEGSEDI-treated patients vs. no patient on placebo. In these patients, stopping TEGSEDI alone was not sufficient to resolve manifestations of glomerulonephritis, and treatment with an immunosuppressive medication was necessary. One patient did not receive immunosuppressive treatment and remained dialysis-dependent. If glomerulonephritis is suspected, pursue prompt diagnosis and initiate immunosuppressive treatment as soon as possible. </paragraph>
                        <paragraph>Cases of glomerulonephritis were accompanied by nephrotic syndrome. Possible complications of nephrotic syndrome can include edema, hypercoagulability with venous or arterial thrombosis, and increased susceptibility to infection. TEGSEDI-treated patients who develop glomerulonephritis will require monitoring and treatment for nephrotic syndrome and its manifestations.</paragraph>
                        <paragraph>Accumulation of antisense oligonucleotides in proximal tubule cells of the kidney, sometimes leading to increased tubular proteinuria, has been described in nonclinical studies. Urine protein to creatinine ratio (UPCR) greater than 5 times the upper limit of normal occurred in 15% of TEGSEDI-treated patients, compared to 8% of patients on placebo. Increase from baseline in serum creatinine greater than 0.5 mg/dL occurred in 11% of TEGSEDI-treated patients, compared to 2% of patients on placebo.</paragraph>
                        <paragraph>Follow recommended monitoring and treatment recommendations for renal parameters <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s_0204">2.4</linkHtml>)]</content> . TEGSEDI should generally not be initiated in patients with a UPCR of 1000 mg/g or greater. If acute glomerulonephritis is confirmed, TEGSEDI should be permanently discontinued <content styleCode="italics">[see Contraindications (<linkHtml href="#s_0400">4</linkHtml>)]</content>. </paragraph>
                        <paragraph>Use caution with nephrotoxic drugs and other drugs that may impair renal function. Because immunosuppressive treatment is necessary for the treatment of glomerulonephritis, avoid using TEGSEDI in patients for whom immunosuppressive treatment is not advised. </paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0503">
                     <id root="0c00027c-b8ca-462b-8658-e19cf20cc5dd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.3 TEGSEDI REMS Program</title>
                     <text>
                        <paragraph>TEGSEDI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TEGSEDI REMS Program, because of risks of serious bleeding caused by severe thrombocytopenia and because of glomerulonephritis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml>, <linkHtml href="#s_0502">5.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>Important requirements of the TEGSEDI Prescribing Program include:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Prescribers must be certified within the program by enrolling and completing training.</item>
                           <item>Patients must enroll in the program and comply with ongoing monitoring requirements <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml>) and Dosage and Administration (<linkHtml href="#s_0204">2.4</linkHtml>)]</content>. Pharmacies must be certified with the program and must only dispense to patients who are authorized to receive TEGSEDI. </item>
                        </list>
                        <content>Further information, including a list of qualified pharmacies/distributors, is available at <linkHtml href="www.TEGSEDIREMS.com">www.TEGSEDIREMS.com</linkHtml> or 1-844-483-4736.</content>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0504">
                     <id root="de01a87c-0196-4e71-bad7-e477ed14c9a7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.4 Stroke and Cervicocephalic Arterial Dissection</title>
                     <text>
                        <paragraph>TEGSEDI may cause stroke and cervicocephalic arterial dissection. In clinical studies, 1 of 161 (0.6%) TEGSEDI-treated patients experienced carotid artery dissection and stroke. These events occurred within 2 days of the first TEGSEDI dose, a time when the patient also had symptoms of cytokine release (e.g., nausea, vomiting, muscular pain and weakness) and a high sensitivity C-reactive protein level greater than 100 mg/L.</paragraph>
                        <paragraph>Educate patients on the symptoms of stroke and central nervous system arterial dissection. Instruct patients to seek help as soon as possible if symptoms of stroke or arterial dissection occur.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0505">
                     <id root="5a3451c8-8ced-4685-bfce-9ff3aff8fdad"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.5 Inflammatory and Immune Effects</title>
                     <text>
                        <paragraph>Inflammatory and immune changes are an effect of some antisense oligonucleotide drugs, including TEGSEDI. In clinical studies, serious inflammatory and immune adverse reactions occurred in TEGSEDI-treated patients, including immune thrombocytopenia and glomerulonephritis, as well as a single case of antineutrophil cytoplasmic autoantibody (ANCA)-positive systemic vasculitis  <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0502">5.2</linkHtml>) and (<linkHtml href="#s_0503">5.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Neurologic Serious Adverse Reactions</content>
                        </paragraph>
                        <paragraph>In clinical studies, neurologic serious adverse reactions consistent with inflammatory and immune effects occurred in TEGSEDI-treated patients, in addition to stroke and carotid artery dissection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0505">5.5</linkHtml>)]</content>. Two months after the first TEGSEDI dose, one patient developed a change in gait that progressed over 6 months to paraparesis, in the absence of radiologic evidence of spinal cord compression. Another patient developed progressive lumbar pain, weight loss, headache, vomiting, and impaired speech 7 months after starting TEGSEDI.  Cerebrospinal fluid analysis findings included elevated protein, a lymphocyte-predominant pleocytosis, and testing that was negative for infection. The patient recovered after empiric therapy (high-dose steroids, antibiotics) and resumed TEGSEDI without recurrence of symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0506">
                     <id root="353f859f-0c96-41fb-b36b-24677d730a18"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.6 Liver Injury</title>
                     <text>
                        <paragraph>The liver is a site of accumulation of antisense oligonucleotides. In clinical studies, 8% of TEGSEDI-treated patients had an increased alanine aminotransferase (ALT) at least 3 times the upper limit of normal (ULN), compared to 3% of patients on placebo; 3% of TEGSEDI-treated patients had an ALT at least 8 times the ULN, compared to no patient on placebo. One clinical study patient experienced an increased ALT more than 30 times the ULN.  After a course of corticosteroids and discontinuation of TEGSEDI, the patientâs ALT returned to normal levels. Some patients had resolution of the liver laboratory abnormalities with continued use of TEGSEDI.</paragraph>
                        <paragraph>In clinical studies, demonstrated or possible cases of immune-mediated biliary disease occurred in TEGSEDI-treated patients. There was a single case of autoimmune hepatitis with primary biliary cirrhosis in a patient with a family history of primary biliary cirrhosis, as well as a single case of biliary obstruction of unclear etiology.</paragraph>
                        <paragraph>Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin at baseline and monthly during treatment with TEGSEDI. If a patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine), promptly measure serum transaminases and total bilirubin and interrupt treatment with TEGSEDI, as appropriate.</paragraph>
                        <paragraph>If a patient is suspected to have developed liver injury induced by TEGSEDI treatment, TEGSEDI should be discontinued.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Liver Transplant Rejection</content>
                        </paragraph>
                        <paragraph>In a clinical study, cases of liver transplant rejection were reported 2-4 months after starting TEGSEDI in patients whose liver allografts had previously been clinically stable (for over 10 years) prior to starting TEGSEDI.  In these cases, the patients clinically improved and transaminase levels normalized after glucocorticoid administration and cessation of TEGSEDI.</paragraph>
                        <paragraph>In patients with a history of liver transplant, monitor ALT, AST, and total bilirubin monthly. Discontinue TEGSEDI in patients who develop signs of liver transplant rejection.</paragraph>
                     </text>
                     <effectiveTime value="20240115"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0507">
                     <id root="810c747c-3518-4e32-9293-f39ee399329f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.7 Hypersensitivity Reactions/Antibody Formation</title>
                     <text>
                        <paragraph>TEGSEDI can cause hypersensitivity reactions. In clinical studies, 6 of 161 (4%) TEGSEDI-treated patients stopped treatment because of a hypersensitivity reaction. Antibodies to TEGSEDI were present when the reactions occurred. These reactions generally occurred within 2 hours of administration of TEGSEDI and included headache, chest pain, hypertension, chills, flushing, dysphagia, palmar erythema, eosinophilia, involuntary choreaform movements, arthralgia, myalgia, and flu-like symptoms.</paragraph>
                        <paragraph>If a hypersensitivity reaction occurs, discontinue administration of TEGSEDI, and initiate appropriate therapy. Do not use in patients who have a history of hypersensitivity reaction to TEGSEDI.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0508">
                     <id root="eea150ca-24ef-4f33-9a17-974e71ad58fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.8 Uninterpretable Platelet Counts: Reaction between Antiplatelet Antibodies and ethylenediaminetetra-acetic acid (EDTA)</title>
                     <text>
                        <paragraph>In Study 1 <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s_1400">14</linkHtml>)]</content>, 23% of TEGSEDI-treated patients had at least 1 uninterpretable platelet count caused by platelet clumping, compared to 13% of patients on placebo. In 2 cases of severe thrombocytopenia with platelet count below 25 x 10<sup>9</sup>/L, one of which resulted in death, clumped platelet samples caused a delay in diagnosis and treatment. Both subjects had tested positive for treatment-emergent anti-platelet IgG antibodies detected shortly before, or at the time of the severe reduction in platelet count.</paragraph>
                        <paragraph>Although platelet clumping can have a variety of causes (e.g., incompletely mixed or inadequately anticoagulated samples), platelet clumping can be caused by a reaction between antiplatelet antibodies and ethylenediaminetetra-acetic acid (EDTA). In Study 1, 7 of the 9 (78%) TEGSEDI-treated patients with treatment-emergent positive antiplatelet antibody testing had at least 1 clumped platelet sample.</paragraph>
                        <paragraph>If there is suspicion of EDTA-mediated platelet clumping, perform a repeat platelet count using a different anticoagulant (e.g., sodium citrate, heparin) in the blood collection tube. Recheck the platelet count as soon as possible if a platelet measurement is uninterpretable. Hold TEGSEDI dosing until an acceptable platelet count is confirmed with an interpretable blood sample.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0509">
                     <id root="c4d822f8-89a7-4148-b6bb-0c0160a30a12"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.9 Reduced Serum Vitamin A Levels and Recommended Supplementation</title>
                     <text>
                        <paragraph>TEGSEDI treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance of vitamin A is advised for patients taking TEGSEDI. Higher doses than the recommended daily allowance of vitamin A should not be given to try to achieve normal serum vitamin A levels during treatment with TEGSEDI, as serum vitamin A levels do not reflect the total vitamin A in the body.</paragraph>
                        <paragraph>Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_0600">
               <id root="6ea0d695-dc5f-41f2-b569-35852dcfdd87"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Thrombocytopenia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml>)]</content>
                     </item>
                     <item>Glomerulonephritis and Renal Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0502">5.2</linkHtml>)]</content>
                     </item>
                     <item>Stroke and Cervicocephalic Arterial Dissection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0504">5.4</linkHtml>)]</content>
                     </item>
                     <item>Inflammatory and Immune Effects <content>[see Warnings and Precautions (<linkHtml href="#s_0505">5.5</linkHtml>)]</content>
                     </item>
                     <item>Liver Injury <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0506">5.6</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0507">5.7</linkHtml>)]</content>
                     </item>
                     <item>Reducted Serum Vitamin A Levels and Recommended Supplementation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0509">5.9</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20210509"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (those that occurred in at least 20% of TEGSEDI-treated patients and more frequently than on placebo) were injection site reactions, nausea, headache, fatigue, thrombocytopenia,  and fever (<linkHtml href="#s_0601">6.1</linkHtml>).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Sobi, Inc. at 1-833-642-5232 or FDA at 1-800-FDA-1088 or <content styleCode="italics">
                                 <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content>.</content>
                        </paragraph>
                        <br/>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s_0601">
                     <id root="5c00ec45-abb9-4ace-9a57-d8f67ed0d102"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of TEGSEDI cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>A total of 112 adult patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) received TEGSEDI in Study 1 and 60 patients received placebo. The, mean age of the study patients was 59 years (27 to 78 years of age). Of the TEGSEDI-treated patients, 69% were male and 94% were Caucasian, with a mean exposure of 385 days, and median exposure of 449 days. Baseline disease characteristics were largely similar in  TEGSEDI-treated patients and patients in the placebo control group.  Sixty-seven percent of patients were in Stage 1 of the disease at baseline, and 33% in Stage 2. Fifty-two percent of patients had Val30Met mutations in the TTR gene, with the remaining 48% comprised of 26 different other point mutations.</paragraph>
                        <paragraph>
                           <linkHtml href="#table2">Table 2</linkHtml> presents common adverse reactions that occurred in at least 5% of TEGSEDI-treated patients and that occurred at least 5% more frequently or two times more frequently than on placebo.</paragraph>
                        <paragraph>The most common adverse reactions that occurred in at least 20% of TEGSEDI-treated patients and more frequently than on placebo were injection site reactions, nausea, headache, fatigue, thrombocytopenia, and fever.  Serious adverse reactions were more frequent in TEGSEDI-treated patients (32%) than in patients on placebo (21%). The most common adverse reactions leading to discontinuation were thrombocytopenia and cachexia.</paragraph>
                        <table styleCode="Noautorules" ID="table2" width="750">
                           <caption>Table 2:	Adverse Reactions Reported in At Least 5% TEGSEDI-Treated Patients and that Occurred At Least 5% More Frequently or At Least Two Times More Frequently than Placebo Patients (Study 1)</caption>
                           <col width="40%" align="left"/>
                           <col width="30%" align="center"/>
                           <col width="30%" align="center"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left">
                                    <sup>a</sup> Includes bruising, erythema, hematoma, hemorrhage, induration, inflammation, mass, edema, pain, pruritus, rash, swelling, and urticaria.<br/>
                                    <sup>b</sup> Includes arrhythmia, atrial fibrillation, atrial flutter, bradyarrhythmia, bradycardia, extrasystoles, sinus arrhythmia, sinus bradycardia, supraventricular extrasystoles, tachycardia, and ventricular extrasystoles.<br/>
                                    <sup>c</sup> Includes bacteremia, cellulitis staphylococcal, clostridium difficile infection, conjunctivitis bacterial, cystitis Escherichia, <content styleCode="italics">Helicobacter</content> gastritis, <content styleCode="italics">Helicobacter</content> infection, Staphylococcal infection.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr valign="middle">
                                 <td styleCode="Toprule Botrule Rrule Lrule"/>
                                 <td styleCode="Toprule Botrule Rrule Lrule">TEGSEDI<br/>
												(N=112)<br/>
												%
											</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">Placebo<br/> 
												(N=60)<br/>
												%
											</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Injection site reactions<sup>a</sup>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">49</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">10</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Nausea</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">31</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">12</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Headache</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">26</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">12</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Fatigue</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">25</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">20</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Thrombocytopenia</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">24</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">2</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Fever</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">20</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">8</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Peripheral edema</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">19</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">10</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Chills</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">18</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">3</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Anemia</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">17</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">3</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Vomiting</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">15</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">5</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Myalgia</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">15</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">10</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Decreased renal function</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">14</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">5</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Arrhythmia<sup>b</sup>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">13</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">5</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Arthralgia</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">13</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">8</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Pre-syncope or syncope</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">13</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">5</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Decreased appetite</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">10</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">0</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Paresthesia</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">10</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">3</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Dyspnea</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">9</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">3</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Elevated liver function  test </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">9</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">3</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Orthostasis</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">8</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">2</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Influenza-like illness</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">8</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">3</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Contusion</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">7</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">2</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Bacterial infection<sup>c</sup>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">7</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">3</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Eosinophilia</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">5</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">0</td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Rrule Lrule">Dry mouth</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">5</td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">2</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20200902"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0602">
                     <id root="d6393349-f7b5-4838-a6a1-0fd47a2b1226"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">6.2 Immunogenicity</title>
                     <text>
                        <paragraph>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. In addition, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to TEGSEDI in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.</paragraph>
                        <paragraph>In Study 1, 30% of TEGSEDI-treated patients tested positive for anti-drug antibodies (ADA) following 65 weeks of treatment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0507">5.7</linkHtml>, <linkHtml href="#s_0508">5.8</linkHtml>)]</content>. However, the assay measured only IgG isotypes and the existence of other isotypes may be possible. In many cases adverse reactions occurred in patients with ADA, although the available data are too limited to make definitive conclusions about the relationship. </paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_0700">
               <id root="6e7f8861-92ab-4984-bc08-b7aeb586deba"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">7 DRUG INTERACTIONS</title>
               <effectiveTime value="20181015"/>
               <component>
                  <section ID="s_0701">
                     <id root="f4b66438-f281-4c53-83bf-7b90782dbf27"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">7.1	Antiplatelet Drugs or Anticoagulant Medications</title>
                     <text>
                        <paragraph>Because of the risk of thrombocytopenia, caution should be used when using antiplatelet drugs (e.g., adenosine, clopidogrel, prasugrel, ticagrelor, or ticlopidine), including non-prescription products that affect platelets (e.g., aspirin, nonsteroidal anti-inflammatory drugs), or anticoagulants (e.g., heparin, warfarin), concomitantly with TEGSEDI <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0702">
                     <id root="e6e4ad33-8f1d-4e1a-9347-075581d7eb2a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">7.2 Nephrotoxic Drugs</title>
                     <text>
                        <paragraph>Because of the risk of glomerulonephritis and renal toxicity, caution should be used when using nephrotoxic drugs and other drugs that may impair renal function concomitantly with TEGSEDI <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0502">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_0800">
               <id root="d4af76d1-189b-4bed-a7fa-df2c1f07cb80"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20200902"/>
               <component>
                  <section ID="s_0801">
                     <id root="58e0ed9a-243c-4679-b69b-59fdea0f2c3a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="Underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to TEGSEDI during pregnancy.  Health care providers are encouraged to register patients and pregnant women are encouraged to register themselves by calling: 1-877-465-7510, emailing:  <linkHtml href="tegsedipregnancy@ubc.com">tegsedipregnancy@ubc.com</linkHtml>, or visiting online at: <linkHtml href="www.tegsedipregnancystudy.com">www.tegsedipregnancystudy.com</linkHtml>.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the developmental risk associated with the use of TEGSEDI in pregnant women. TEGSEDI treatment leads to a decrease in serum vitamin A levels, and vitamin A supplementation is advised for patients taking TEGSEDI.  Vitamin A is essential for normal embryofetal development; however, excessive levels of Vitamin A are associated with adverse developmental effects. The effects on the fetus of a reduction in maternal serum TTR caused by TEGSEDI and of vitamin A supplementation are unknown <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s_1202">12.2</linkHtml>), Warnings and Precautions (<linkHtml href="#s_0509">5.9</linkHtml>)]</content>.</paragraph>
                        <paragraph>In animal studies, subcutaneous administration of inotersen to pregnant rabbits resulted in premature delivery and reduced fetal body weight at the highest dose tested, which was associated with maternal toxicity. No adverse developmental effects were observed when inotersen or a pharmacologically-active surrogate was administered to pregnant mice. </paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Subcutaneous administration of inotersen (0, 3, 15, or 25 mg/kg) or a rodent-specific surrogate (15 mg/kg) to male and female mice every other day prior to and during mating and continuing in females throughout the period of organogenesis produced no adverse effects on embryofetal development.</paragraph>
                        <paragraph>Subcutaneous administration of inotersen (0, 2.5, 5, or 15 mg/kg) to pregnant rabbits every other day throughout the period of organogenesis resulted in premature delivery and reduced fetal body weight at the highest dose tested, which was associated with maternal toxicity (reduced body weight and food consumption).</paragraph>
                        <paragraph>Subcutaneous administration of inotersen (0, 2.9, 11.4, or 22.9 mg/kg) or a rodent-specific surrogate (11.4 mg/kg) to mice every other day throughout pregnancy and lactation produced no adverse effects on pre- or postnatal development.</paragraph>
                     </text>
                     <effectiveTime value="20200902"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0802">
                     <id root="4b9d55bc-6eeb-42a1-958f-7142241a2e1e"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="Underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of TEGSEDI  in human milk, the effects on the breast-fed infant, or the effects on milk production. A study in lactating mice has shown excretion of inotersen in milk. The development and health benefits of breastfeeding should be considered along with the motherâs clinical need for TEGSEDI  and any potential adverse effects on the breastfed infant from TEGSEDI or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0804">
                     <id root="0ff9bf97-bc9e-4f24-9f42-46cea07677ec"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0805">
                     <id root="d383b419-b14d-449c-9d5d-5d0a52de6a44"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of TEGSEDI included 69 patients (45%) aged 65 and over. No differences in pharmacokinetics or effectiveness were observed between these patients and younger patients.  Patients 65 years and older may be at increased risk of certain adverse reactions, such as congestive heart failure, chills, myalgia, and extremity pain.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0806">
                     <id root="62a0a06e-5872-4531-b8db-73920bcef6b1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.6 Renal Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is necessary in patients with mild to moderate renal impairment (estimated glomerular filtration rate [eGFR] â¥30 to &lt;90 mL/min/1.73 m<sup>2</sup>) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s_1203">12.3</linkHtml>)]</content>. TEGSEDI has not been studied in patients with severe renal impairment or end-stage renal disease.</paragraph>
                     </text>
                     <effectiveTime value="20200902"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0807">
                     <id root="a966036c-ba11-4554-acc1-68c3d2bb3b1d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is necessary in patients with mild hepatic impairment <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s_1203">12.3</linkHtml>)]</content>. TEGSEDI has not been studied in patients with other degrees of hepatic impairment. </paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_1100">
               <id root="03669bd9-e8ec-4d2e-881b-8238a3cd9da1"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title mediaType="text/x-hl7-title+xml">11 DESCRIPTION</title>
               <text>
                  <paragraph>Inotersen is an antisense oligonucleotide (ASO) inhibitor of human transthyretin (TTR) protein synthesis.</paragraph>
                  <paragraph>TEGSEDI contains inotersen sodium as the active ingredient. Inotersen sodium is a white to pale yellow solid and it is freely soluble in water and in phosphate buffer (pH 7.5 to 8.5). The chemical name of inotersen sodium is DNA, d(<content styleCode="italics">P</content>-thio)([2'-<content styleCode="italics">O</content>-(2-methoxyethyl)]m<sup>5</sup>rU-[2'-<content styleCode="italics">O</content>-(2-methoxyethyl)]m<sup>5</sup>rC-[2'-<content styleCode="italics">O</content>-(2-methoxyethyl)]m<sup>5</sup>rU-[2'-<content styleCode="italics">O</content>-(2-methoxyethyl)]m<sup>5</sup>rU-[2'-<content styleCode="italics">O</content>-(2-methoxyethyl)]rG-G-T-T-A-m<sup>5</sup>C-A-T-G-A-A-[2'-<content styleCode="italics">O</content>-(2-methoxyethyl)]rA-[2'-<content styleCode="italics">O</content>-(2-methoxyethyl)]m<sup>5</sup>rU-[2'-<content styleCode="italics">O</content>-(2-methoxyethyl)]m<sup>5</sup>rC-[2'-<content styleCode="italics">O</content>-(2-methoxyethyl)]m<sup>5</sup>rC-[2'-<content styleCode="italics">O</content>-(2-methoxyethyl)]m<sup>5</sup>rC). The molecular formula of inotersen sodium is C<sub>230</sub>H<sub>299</sub>N<sub>69</sub> Na<sub>19</sub>O<sub>121</sub>P<sub>19</sub>S<sub>19</sub> and the molecular weight is 7600.73 Da. It has the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM001"/>
                  </paragraph>
                  <paragraph>The molecular formula of inotersen free base is C<sub>230</sub>H<sub>318</sub>N<sub>69</sub>O<sub>121</sub>P<sub>19</sub>S<sub>19</sub> and its molecular weight is 7183.08.</paragraph>
                  <paragraph>TEGSEDI is a sterile, preservative-free, aqueous solution for subcutaneous injection. It is supplied in a prefilled syringe (PFS). Each PFS contains 1.5 mL of solution containing 284 mg inotersen (equivalent to 300 mg inotersen sodium salt) TEGSEDI is formulated in Water for Injection and may include hydrochloric acid and/or sodium hydroxide for pH adjustment to 7.5-8.5.</paragraph>
               </text>
               <effectiveTime value="20181015"/>
               <component>
                  <observationMedia ID="MM001">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_1200">
               <id root="ca8d87ad-58bb-4ea3-9274-a3c264128f0c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title mediaType="text/x-hl7-title+xml">12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20200902"/>
               <component>
                  <section ID="s_1201">
                     <id root="f0655897-0c48-4091-8c19-bddec503e3f8"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Inotersen is an antisense oligonucleotide that causes degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_1202">
                     <id root="e46ca16c-d1ba-4d79-a862-91129a283ddf"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The pharmacodynamic effects of TEGSEDI were evaluated in hATTR amyloidosis patients treated with 284 mg TEGSEDI via subcutaneous injection once weekly.</paragraph>
                        <paragraph>With repeat dosing, the mean percent decreases from baseline in serum TTR from Week 13 to Week 65 of treatment ranged from 68% to 74% (median range: 75% to 79%). Similar TTR reductions were observed regardless of TTR mutation, sex, age, or race.</paragraph>
                        <paragraph>Serum TTR is a carrier of retinol binding protein, which is involved in the transport of vitamin A in the blood. Mean reductions in serum retinol binding of 71%, and serum vitamin A of 63%, were observed at Week 65 <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0506">5.6</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>Formal QTc studies have not been conducted with TEGSEDI. The potential for QTc prolongation with inotersen was evaluated in a randomized, placebo-controlled trial in healthy volunteers. No large changes in the mean QTc interval (&gt;20 ms) were detected in the trial.</paragraph>
                        <paragraph>In the 66-week controlled efficacy trial, 5.4% of TEGSEDI-treated patients had evidence of QRS prolongation on their electrocardiograms (ECGs) to greater than 160 msec and greater than 25% above baseline, compared to and in 1.7% of patients on placebo.</paragraph>
                     </text>
                     <effectiveTime value="20181015"/>
                  </section>
               </component>
               <component>
                  <section ID="s_1203">
                     <id root="2320ac73-afb0-4538-b11d-3926e9cadcd5"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Following subcutaneous administration, systemic exposure to inotersen increased in a dose-proportional manner over the range of 150-400 mg of inotersen sodium salt. At the recommended TEGSEDI dosing regimen of 284 mg every week, steady state is reached after approximately 3 months. The estimated geometric mean (90% confidence interval) steady state peak concentrations (Cmax), trough concentrations (Ctrough), and area under the curve (AUCÏ) were 6.39 (5.65, 7.20) Âµg/mL, 0.034 (0.031, 0.038) Âµg/mL, and 90 (82.4, 97.4) ÂµgÂ·h/mL, respectively. Plasma Cmax and AUC do not exhibit accumulation at steady state. </paragraph>
                        <paragraph>
                           <content styleCode="Underline">Absorption</content>
                        </paragraph>
                        <paragraph>Following subcutaneous administration, TEGSEDI is absorbed rapidly into systemic circulation in a dose-dependent fashion, with the median time to maximum plasma concentrations (C<sub>max</sub>) of 2 to 4 hours. </paragraph>
                        <paragraph>
                           <content styleCode="Underline">Distribution</content>
                        </paragraph>
                        <paragraph>TEGSEDI is highly bound to human plasma proteins (&gt;94%) and the fraction bound is independent of drug concentration. Based on animal studies (mouse, rat and monkey), TEGSEDI rapidly distributes broadly to tissues, with the highest concentrations observed in the kidney and liver. TEGSEDI does not cross the blood-brain barrier. The apparent volume of distribution of TEGSEDI at steady-state (mean and 90% confidence interval) is 293 (268, 320) L in patients with hATTR.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Elimination</content>
                        </paragraph>
                        <paragraph>The terminal elimination half-life (mean and 90% confidence interval) for TEGSEDI is 32.3 (29.4, 35.5) days. Inotersen is mainly cleared through metabolism, and the total body clearance (mean and 90% confidence interval) is 3.18 (3.08, 3.29) L/h.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Inotersen is metabolized by nucleases to nucleotides of various lengths.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Less than 1% of the administered dose of inotersen is excreted unchanged into urine within 24 hours.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>Age, race, and sex had no impact on the steady state pharmacokinetics of inotersen or TTR reduction. Population pharmacokinetic and pharmacodynamic analyses indicated no impact of mild or moderate renal impairment (eGFR â¥30 to &lt;90 mL/min/1.73 m<sup>2</sup>) or mild hepatic impairment (bilirubin less than or equal to 1.5 x ULN and/or AST less than 1.9 x ULN) on inotersen exposure or TTR reduction. TEGSEDI has not been studied in patients with severe renal impairment, end-stage renal disease, moderate or severe hepatic impairment, or in patients with prior liver transplant.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>No formal clinical drug interaction studies have been performed. TEGSEDI is not a substrate or inhibitor/inducer of major CYP enzymes or a substrate or inhibitor of major transporters. In a population pharmacokinetic analysis, concomitant use of diuretics, antithrombotic, and analgesics did not impact the pharmacokinetic parameters of inotersen. TEGSEDI is not expected to cause drug-drug interactions or to be affected by inhibitors or inducers of cytochrome P450 enzymes.</paragraph>
                     </text>
                     <effectiveTime value="20200902"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_1300">
               <id root="ccf75242-d780-46a6-8d33-8389a97fbed5"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title mediaType="text/x-hl7-title+xml">13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20220629"/>
               <component>
                  <section ID="s_1301">
                     <id root="817ee3c3-188c-47a7-869d-950d100ef75a"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>In a 26-week carcinogenicity study in transgenic (TgRasH2) mice, weekly subcutaneous administration of inotersen (0, 10, 30, or 80 mg/kg) or a rodent-specific (pharmacologically active) surrogate (30 mg/kg) did not result in an increase in tumors.</paragraph>
                        <paragraph>In a 94-week carcinogenicity study in rats, weekly subcutaneous administration of inotersen (0, 0.5, 2, or 6 mg/kg) resulted in an increase in tumors at or near the injection site in males at all but the lowest dose (0.5 mg/kg) tested. Subcutaneous malignant pleomorphic fibrosarcoma was increased at the mid and high doses and combined subcutaneous malignant pleomorphic fibrosarcoma and monomorphic fibrosarcoma were increased at the high dose. These tumors are considered a response to chronic tissue irritation and inflammation caused by repeated subcutaneous injection.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Inotersen was negative for genotoxicity in <content styleCode="italics">in vitro</content> (bacterial mutagenicity, chromosomal aberration in Chinese hamster lung) and <content styleCode="italics">in vivo</content> (mouse bone marrow micronucleus) assays.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Subcutaneous administration of inotersen (0, 3, 15, or 25 mg/kg) or a rodent-specific surrogate (15 mg/kg) to male and female mice every other day prior to and during mating and continuing in females throughout the period of organogenesis produced no adverse effects on fertility.</paragraph>
                     </text>
                     <effectiveTime value="20220629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_1400">
               <id root="967b8d53-9794-4f62-8ad8-58a75ca742e2"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title mediaType="text/x-hl7-title+xml">14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of TEGSEDI was demonstrated in a randomized, double-blind, placebo-controlled, multicenter clinical trial in adult patients with polyneuropathy caused by hATTR amyloidosis (Study 1; NCT 01737398). Patients were randomized in a 2:1 ratio to receive either TEGSEDI (284 mg inotersen) (N=113) or placebo (N=60), respectively, as a subcutaneous injection administered once per week for 65 weeks (3 doses were administered during the first week of treatment). Seventy seven percent of TEGSEDI-treated patients and 87% of patients on placebo completed 66 weeks of the assigned treatment.</paragraph>
                  <paragraph>The co-primary efficacy endpoints were the change from baseline to Week 66 in the modified Neuropathy Impairment Scale+7 (mNIS+7) composite score and the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score</paragraph>
                  <paragraph>The mNIS+7 is an objective assessment of neuropathy, and comprises the NIS and Modified +7 composite scores. In the version of the mNIS+7 used in the trial, the NIS objectively measures deficits in cranial nerve function, muscle strength, reflexes, and sensations, and the Modified +7 assesses heart rate response to deep breathing, postural blood pressure, quantitative sensory testing (touch-pressure and heat-pain), and peripheral nerve electrophysiology. The maximum possible score was 346.32 points, with higher scores representing a greater severity of disease.</paragraph>
                  <paragraph>The clinical meaningfulness of effects on the mNIS+7 was assessed by the change from baseline to Week 66 in Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score. The Norfolk QoL-DN scale is a patient-reported assessment that evaluates the subjective experience of neuropathy in the following domains: physical functioning/large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The version of the Norfolk QoL-DN that was used in the trial had a maximum possible total score of 136 points, with higher scores representing greater impairment.</paragraph>
                  <paragraph>The changes from baseline to Week 66 on both the mNIS+7 and the Norfolk QoL-DN significantly favored TEGSEDI (<linkHtml href="#table3">Table 3</linkHtml>, <linkHtml href="#figure1">Figures 1</linkHtml> and <linkHtml href="#figure3">3</linkHtml>). The distributions of changes in mNIS+7 and Norfolk QoL-DN scores from baseline to Week 66 by percent of patients are shown in Figure 2 and Figure 4, respectively.</paragraph>
                  <table ID="table3" width="800" styleCode="Noautorules">
                     <caption>Table 3:  Clinical Efficacy Results from Study 1</caption>
                     <col width="25%" align="center"/>
                     <col width="12%" align="center"/>
                     <col width="13%" align="center"/>
                     <col width="12%" align="center"/>
                     <col width="13%" align="center"/>
                     <col width="15%" align="center"/>
                     <col width="10%" align="center"/>
                     <tfoot>
                        <tr>
                           <td colspan="7" align="left">CI, confidence interval; LS, least squares; mNIS, modified Neuropathy Impairment Score; QoL-DN, Quality of Life â Diabetic Neuropathy<br/>
                              <sup>a</sup> All endpoints analyzed using the mixed-effect model repeated measures (MMRM) method.<br/>
                              <sup>b</sup> A lower value indicates less impairment/fewer symptoms.<br/>
                              <sup>c</sup>The primary analysis population for the mNIS+7 analysis included N=95 TEGSEDI patients and N=56 placebo patients<br/>
                              <sup>d</sup>The primary analysis population for the Norfolk QOL-DN analysis included N=94 TEGSEDI patients and N=57 placebo patients</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr valign="middle">
                           <td rowspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Endpoint</content>
                           </td>
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Baseline</content>
                           </td>
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Change from Baseline to<br/> Week 66 (LS Mean)</content>
                           </td>
                           <td rowspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">TEGSEDI â placebo Treatment Difference LS Mean
										(95% CI)</content>
                           </td>
                           <td rowspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold italics">p</content>
                              <content styleCode="bold">-<br/>value</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td align="center" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">TEGSEDI</content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Placebo</content>
                           </td>
                           <td align="center" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">TEGSEDI</content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Placebo</content>
                           </td>
                        </tr>
                        <tr valign="middle">
                           <td colspan="7" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Primary<sup>a</sup>
                              </content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">mNIS+7<sup>b, c</sup>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule" valign="middle">80.2</td>
                           <td styleCode="Toprule Botrule Lrule Rrule" valign="middle">75.3 </td>
                           <td styleCode="Toprule Botrule Lrule Rrule" valign="middle">5.8</td>
                           <td styleCode="Toprule Botrule Lrule Rrule" valign="middle">25.5</td>
                           <td styleCode="Toprule Botrule Lrule Rrule" valign="middle">-19.7 
										<br/>[-26.4, -13.0]
									</td>
                           <td styleCode="Toprule Botrule Lrule Rrule">&lt;0.001</td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">Norfolk QOL-<br/>DN<sup>b, d</sup>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule" valign="middle">48.7</td>
                           <td styleCode="Toprule Botrule Lrule Rrule" valign="middle">48.7</td>
                           <td styleCode="Toprule Botrule Lrule Rrule" valign="middle">1.0</td>
                           <td styleCode="Toprule Botrule Lrule Rrule" valign="middle">12.7</td>
                           <td styleCode="Toprule Botrule Lrule Rrule" valign="middle">-11.7  
										<br/>[-18.3, -5.1]
									</td>
                           <td styleCode="Toprule Botrule Lrule Rrule">&lt;0.001</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="figure1">
                     <content styleCode="bold">Figure 1: Change from Baseline in mNIS+7</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM002"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2: Histogram of mNIS+7 Change from Baseline at Week 66</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM003"/>
                  </paragraph>
                  <paragraph ID="figure3">
                     <content styleCode="bold">Figure 3: Change from Baseline in Norfolk QoL-DN Score</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM004"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 4: Histogram of Norfolk QoL-DN Change from Baseline at Week 66</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM005"/>
                  </paragraph>
                  <paragraph>Patients receiving TEGSEDI experienced similar improvements relative to placebo in mNIS+7 and Norfolk QoL-DN score across all subgroups including age, sex, race, region, NIS score, Val30Met mutation status, and disease stage.</paragraph>
               </text>
               <effectiveTime value="20200902"/>
               <component>
                  <observationMedia ID="MM002">
                     <text>Figure 1: Change from Baseline in mNIS+7</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM003">
                     <text>Figure 2: Histogram of mNIS+7 Change from Baseline at Week 66</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM004">
                     <text>Figure 3: Change from Baseline in Norfolk QoL-DN Score</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM005">
                     <text>Figure 4: Histogram of Norfolk QoL-DN Change from Baseline at Week 66</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_1600">
               <id root="8fc41751-9241-4d45-bca8-940a089467af"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title mediaType="text/x-hl7-title+xml">16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>TEGSEDI is a clear, colorless to pale yellow solution supplied in a single-dose, prefilled syringe with a SSD. Each prefilled syringe of TEGSEDI is filled to deliver 1.5 mL of solution containing 284 mg of inotersen (equivalent to 300 mg inotersen sodium salt).</paragraph>
                  <paragraph>TEGSEDI is available in cartons containing 1 or 4 prefilled syringes supplied in individual trays.</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Pack of 1 prefilled syringe: NDC 72126-007-03</item>
                     <item>Pack of 4 prefilled syringes: NDC 72126-007-01</item>
                  </list>
                  <paragraph>The individual tray of 1 syringe is NDC 72126-007-02.</paragraph>
                  <paragraph>
                     <content styleCode="Underline">Pharmacy</content>
                  </paragraph>
                  <paragraph>Store refrigerated at 2Â°C to 8Â°C (36Â°F to 46Â°F) in the original container and protect from direct light. Do not freeze.</paragraph>
                  <paragraph>
                     <content styleCode="Underline">For Patients/Caregivers</content>
                  </paragraph>
                  <paragraph>Store refrigerated at 2Â°C to 8Â°C (36Â°F to 46Â°F) in the original container. Do not freeze. TEGSEDI can be kept at room temperature (up to 30Â°C [86Â°F]) in the original container for up to 6 weeks; if not used within the 6 weeks, discard TEGSEDI.</paragraph>
                  <paragraph>Remove from refrigerated storage (2Â°C to 8Â°C [36Â°F to 46Â°F]) at least 30 minutes before use. [TEGSEDI] prefilled syringe should be allowed to reach room temperature prior to injection.</paragraph>
                  <paragraph>Avoid exposure to temperatures above 30Â°C (86Â°F).</paragraph>
               </text>
               <effectiveTime value="20191015"/>
            </section>
         </component>
         <component>
            <section ID="s_1700">
               <id root="54770f4e-10d3-4c28-b2ce-8dca79e661df"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient and caregiver to read the FDA-approved patient labeling (<linkHtml href="#Medguide">Medication Guide</linkHtml> and <linkHtml href="#s_ifu">Instructions for Use</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="Underline">Thrombocytopenia</content>
                  </paragraph>
                  <paragraph>Inform patients that TEGSEDI can cause reductions in platelet count that may result in thrombocytopenia. Instruct patients to notify a healthcare provider immediately if they show symptoms of thrombocytopenia (e.g., unusual or prolonged bleeding, neck stiffness, or atypical severe headache). Advise patients of the importance of monitoring during treatment with TEGSEDI <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0501">5.1</linkHtml>)]</content>. Also instruct patients to notify their healthcare provider of all medications, including over-the-counter, that they are taking <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s_0701">7.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="Underline">Glomerulonephritis and Renal Toxicity</content>
                  </paragraph>
                  <paragraph>Inform patients that glomerulonephritis has occurred in patients treated with TEGSEDI. Advise patients of the importance of monitoring of urine protein to creatinine ratio (UPCR during treatment with TEGSEDI) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0502">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="Underline">TEGSEDI REMS Program</content>
                  </paragraph>
                  <paragraph>TEGSEDI is available only through a restricted program called the TEGSEDI REMS Program <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0503">5.3</linkHtml>)]</content>. Inform the patient of the following notable requirements:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Patients must enroll in the program and comply with ongoing monitoring requirements.</item>
                     <item>TEGSEDI is available only from certified pharmacies participating in the program. Therefore, provide patients with the telephone number and website for information on how to obtain the product.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Underline">Stroke and Cervicocephalic Arterial Dissection</content>
                  </paragraph>
                  <paragraph>Educate patient on symptoms of stroke and central nervous system arterial dissection and instruct them to seek help as soon as possible if symptoms of these or other serious neurologic adverse reactions occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0504">5.4</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="Underline">Liver Injury</content>
                  </paragraph>
                  <paragraph>Instruct patients to inform a healthcare professional of symptoms suggestive of hepatic dysfunction that occur after administration of TEGSEDI <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0506">5.6</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="Underline">Hypersensitivity</content>
                  </paragraph>
                  <paragraph>Instruct patients to inform a healthcare professional of symptoms suggestive of hypersensitivity that occur after administration of TEGSEDI <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0507">5.7</linkHtml>)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="Underline">Recommended Vitamin A Supplementation</content>
                  </paragraph>
                  <paragraph>Inform patients that TEGSEDI treatment leads to a decrease in vitamin A levels measured in the serum. Instruct patients to take the recommended daily allowance of vitamin A. Advise patients to contact their healthcare provider if they experience ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness) and refer them to an ophthalmologist if they develop these symptoms <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s_0509">5.9</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="Underline">Administration Instructions</content>
                  </paragraph>
                  <paragraph>Train patients and caregivers on proper subcutaneous administration technique and how to use the single-dose prefilled syringe. Instruct patients and/or caregivers to read and follow the Instructions for Use each time they use TEGSEDI.</paragraph>
                  <paragraph>
                     <content styleCode="Underline">Pregnancy</content>
                  </paragraph>
                  <paragraph>Instruct patients that if they are pregnant or plan to become pregnant while taking TEGSEDI they should inform their healthcare provider. Advise female patients of childbearing potential of the potential risk to the fetus. Encourage patients to enroll in the TEGSEDI Pregnancy Registry if they become pregnant while taking TEGSEDI  <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s_0801">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>For more information about TEGSEDI, go to www.TEGSEDIREMS.com or call 1-844-483-4736</paragraph>
                  <br/>
                  <paragraph>Distributed by:
							<br/>Sobi, Inc.
							<br/>Waltham, MA 02451</paragraph>
                  <br/>
                  <paragraph>TEGSEDI is a registered trademark of Akcea Therapeutics, Inc.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20210509"/>
            </section>
         </component>
         <component>
            <section ID="Medguide">
               <id root="08c9aa26-6f95-49e2-b297-9f8df3901019"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%" styleCode="Noautorules">
                     <col width="34%" align="left"/>
                     <col width="33%" align="left"/>
                     <col width="33%" align="left"/>
                     <tfoot>
                        <tr valign="top">
                           <td align="left" colspan="2">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="center">Issued: 01/2024</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule" align="center">
                              <paragraph>
                                 <content styleCode="bold">MEDICATION GUIDE</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">TEGSEDI (Teg-SED-ee)
											<br/>(inotersen) 
											<br/>injection, for subcutaneous use</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about TEGSEDI?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">TEGSEDI can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">low platelet counts (thrombocytopenia).</content>  TEGSEDI may cause the number of platelets in your blood to be reduced reduced at any time during treatment. 
												This is a common side effect of TEGSEDI.  When your platelet count is too low, your body cannot form clots. 
												You could have serious bleeding that could lead to death.  
												<content styleCode="bold">Call your healthcare provider immediately if you have:</content>
                                    <list>
                                       <item>unusual bruising or a rash of tiny reddish-purple spots, often on the lower legs</item>
                                       <item>bleeding from skin cuts that does not stop or oozes</item>
                                       <item>bleeding from your gums or nose</item>
                                       <item>blood in your urine or stools</item>
                                       <item>bleeding into the whites of your eyes</item>
                                       <item>sudden severe headaches or neck stiffness</item>
                                       <item>vomiting or coughing up blood</item>
                                       <item>abnormal or heavy periods (menstrual bleeding)</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">kidney inflammation (glomerulonephritis).</content>Your kidneys may stop working 
												properly. Glomerulonephritis can lead to severe kidney damage and kidney failure that needs dialysis.
												<content styleCode="bold">Call your healthcare provider immediately if you have:</content>
                                    <list>
                                       <item>puffiness or swelling in your face, feet or hands</item>
                                       <item>new onset or worsening shortness of breath and coughing</item>
                                       <item>blood in your urine or brown urine</item>
                                       <item>foamy urine (proteinuria)</item>
                                       <item>passed less urine than usual</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>Your healthcare provider will do laboratory tests to check your platelet count and kidneys before you start 
											TEGSEDI and while you are using it.  Your healthcare provider should also do laboratory tests for 8 weeks after you stop 
											TEGSEDI.  <content styleCode="bold">It is important that you make sure you get these laboratory tests done.</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Because of the risk of serious bleeding caused by low platelet counts and because of the 
												risk of kidney problems, TEGSEDI is available only through a restricted program called the TEGSEDI Risk Evaluation
												and Mitigation (REMS) Program.</content>
                                    <list>
                                       <item>Before you begin using TEGSEDI, you must enroll in the TEGSEDI REMS Program.  Talk to your healthcare
														provider about how to enroll in the TEGSEDI REMS Program.</item>
                                       <item>
                                          <content styleCode="bold">You must agree to get your laboratory testing done while you are in the TEGSEDI REMS Program.</content>
                                       </item>
                                       <item>You can only get TEGSEDI from a certified pharmacy that participates in the TEGSEDI REMS Program.  Your healthcare provider can give you information on how to find a certified pharmacy.</item>
                                       <item>For more information, including a list of certified pharmacies go to www.TEGSEDIREMS.com or call 1-844-483-4736.</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is TEGSEDI?</content>
                              </paragraph>
                              <paragraph>TEGSEDI is a medicine used to treat the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. 
											It is not known if TEGSEDI is safe and effective in children. 
										</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Do not use TEGSEDI if you have:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>a platelet count that is low. </item>
                                 <item>had kidney inflammation (glomerulonephritis) caused by TEGSEDI.</item>
                                 <item>had an allergic reaction to inotersen or any of the ingredients in TEGSEDI. See the end of this Medication Guide for a complete list of ingredients in TEGSEDI.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before you start using TEGSEDI, tell your healthcare provider about all your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have or had bleeding problems</item>
                                 <item>have or had kidney problems</item>
                                 <item>have received a liver transplant</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if TEGSEDI can harm your unborn baby.
											<list listType="unordered" styleCode="Disc">
                                       <item>There is a registry for women who become pregnant during treatment with TEGSEDI.  If you become pregnant while taking TEGSEDI, talk to your healthcare provider about registering with the TEGSEDI Pregnancy Exposure Registry.   The purpose of this registry is to collect information about your health and your babyâs health.  You can get more information about this registry by calling: 1-877-465-7510, emailing:  <linkHtml href="tegsedipregnancy@ubc.com">tegsedipregnancy@ubc.com</linkHtml>, or visiting online at: <linkHtml href="www.tegsedipregnancystudy.com">www.tegsedipregnancystudy.com</linkHtml>.</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are breastfeeding or plan to breastfeed. It is not known if TEGSEDI can pass into your breast milk or harm your baby. Talk with your healthcare provider about the best way to feed your baby while you are using TEGSEDI.</item>
                              </list>
                              <paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, 
											and herbal supplements.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your healthcare provider if you take:</content>
                              </paragraph>
                              <list>
                                 <item>Vitamin A or beta-carotene supplements. Your healthcare provider should tell you to take vitamin A, but only take the amount they tell you to take. </item>
                                 <item>blood thinners (anticoagulants) or medicines that affect blood clotting. </item>
                                 <item>Ask your healthcare provider or pharmacist if you are not sure if you take any of these medicines.  Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I use TEGSEDI?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read the detailed <content styleCode="bold">Instructions for Use</content> that come with your TEGSEDI.</item>
                                 <item>Your healthcare provider will show you or your caregiver how to inject TEGSEDI the first time. </item>
                                 <item>If you or your caregiver have any questions, ask your healthcare provider.</item>
                                 <item>TEGSEDI is injected under your skin (subcutaneously) in your stomach area (abdomen), or the front of your upper legs (thighs) by you or a caregiver.  A caregiver may also give you an injection of TEGSEDI in the outer area of your upper arm.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into the same site each time.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into the 2-inch area around the belly-button (naval).</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject where the skin is bruised, tender, red, or hard.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into areas with scars or tattoos.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject through clothing.</item>
                                 <item>Follow your healthcare providerâs instructions on when to inject TEGSEDI.</item>
                                 <item>TEGSEDI should be injected 1 time each week on the same day.</item>
                                 <item>If you miss a dose, take the missed dose as soon as possible, unless your next scheduled dose is within 2 days. 
												If your next scheduled dose is within 2 days, skip the missed dose and take your next scheduled dose on the scheduled day.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are possible side effects of TEGSEDI?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">TEGSEDI may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See <content styleCode="bold">âWhat is the most important information I should know about TEGSEDI?â</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">stroke.  </content>TEGSEDI may cause a stroke.  One person taking TEGSEDI had a stroke, 
												which occurred within 2 days after the first dose.Signs or symptoms of stroke may include:
												<list>
                                       <item>sudden numbness or weakness especially on one side of the body</item>
                                       <item>severe headache or neck pain</item>
                                       <item>confusion</item>
                                       <item>problems with vision, speech, or balance</item>
                                       <item>droopy eyelids</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Get emergency help immediately if you have symptoms of stroke.</content>
                              </paragraph>
                              <list>
                                 <item>
                                    <content styleCode="bold">inflammatory and immune system problems.</content>Some people taking TEGSEDI had serious
												inflammatory and immune system problems.  Symptoms of inflammatory and immune system problems included unexpected 
												change in walking, weakness and spasms in legs, back pain, weight loss, headache, vomiting, and problems with speech. 
											</item>
                                 <item>
                                    <content styleCode="bold">liver effects.  </content>TEGSEDI may cause liver problems.  Your healthcare provider 
												should do laboratory tests to check your liver before you start TEGSEDI and while you are using it.  Tell your 
												healthcare provider if you have symptoms that your liver may not be working right, which could include unexpected
												nausea and vomiting, stomach pain, being not hungry, yellowing of the skin, or having dark urine. </item>
                                 <item>
                                    <content styleCode="bold">allergic reactions.  </content> TEGSEDI may cause serious allergic reactions. 
												These allergic reactions often occur within 2 hours after injecting TEGSEDI.  Get emergency help immediately if 
												you have any symptoms of an allergic reaction including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Toprule Botrule Lrule Rrule" valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item styleCode="Toprule Botrule Lrule Rrule">joint pain</item>
                                 <item styleCode="Toprule Botrule Lrule Rrule">chills</item>
                                 <item styleCode="Toprule Botrule Lrule Rrule">redness on palms of hands</item>
                                 <item styleCode="Toprule Botrule Lrule Rrule">muscle pain</item>
                              </list>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item styleCode="Toprule Botrule Lrule Rrule">chest pain</item>
                                 <item styleCode="Toprule Botrule Lrule Rrule">flushing</item>
                                 <item styleCode="Toprule Botrule Lrule Rrule">tremor or jerking movements</item>
                                 <item styleCode="Toprule Botrule Lrule Rrule">flu-like symptoms</item>
                              </list>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item styleCode="Toprule Botrule Lrule Rrule">high blood pressure</item>
                                 <item styleCode="Toprule Botrule Lrule Rrule">difficulty swallowing</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <list>
                                 <item>
                                    <content styleCode="bold">eye problems (low vitamin A levels).  </content>Treatment with TEGSEDI will lower the 
												Vitamin A levels in your blood.  Your healthcare provider should tell you to take Vitamin A supplements while using 
												TEGSEDI. Your healthcare provider will tell you how much to take.  Call your healthcare provider if you get eye 
												problems, such as having difficulty seeing at night or in low lit areas (night blindness). Your healthcare provider 
												should send you to see an eye doctor (ophthalmologist).</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of TEGSEDI include:</content> injection site reactions 
											(such as redness or pain at the injection site), nausea, headache, tiredness, low platelet counts (thrombocytopenia), 
											and fever.</paragraph>
                              <paragraph>These are not all the possible side effects of TEGSEDI. </paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store TEGSEDI?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store TEGSEDI in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C) in the original container.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> freeze.</item>
                                 <item>TEGSEDI prefilled syringes can also be kept at room temperature that is no higher than 86Â°F (30Â°C) in the original container for up to 6 weeks.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> let TEGSEDI reach temperatures above 86Â°F (30Â°C).</item>
                                 <item>If you do not use TEGSEDI kept at room temperature within 6 weeks, throw it away.  </item>
                                 <item>Protect from light.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep TEGSEDI and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of TEGSEDI</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. 
											Do not use TEGSEDI for a condition for which it has not been prescribed.  Do not give TEGSEDI to other people, even 
											if they have the same symptoms that you have. It may harm them.  You can ask your pharmacist or healthcare provider for
											information about TEGSEDI that was written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in TEGSEDI? Active ingredients: </content>inotersen</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients: </content>purified water (water for injection), hydrochloric acid and or sodium hydroxide for pH adjustment</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>Distributed by Sobi, Inc, Waltham, MA  
											<br/>TEGSEDI is registered in the US Patent and Trademark OfficeÂ© 2017 
											<br/>For more information about TEGSEDI, contact Sobi, Inc., at 1-844-483-4736 or go to www.TEGSEDIREMS.com.
											<br/>
                                 <br/>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
               </text>
               <effectiveTime value="20240115"/>
            </section>
         </component>
         <component>
            <section ID="s_ifu">
               <id root="7d379681-996d-4edf-88d3-1a15777b5985"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <table width="100%" styleCode="Noautorules">
                     <col width="60%" align="left"/>
                     <col width="40%" align="left"/>
                     <tfoot>
                        <tr valign="top">
                           <td align="left">This Instructions for Use has been approved by the U.S. Food and Drug Administration</td>
                           <td align="center">Issued:10/2018</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule" align="left">
                              <paragraph>
                                 <content styleCode="bold">TEGSEDI (Teg-SED-ee)</content>
                                 <br/>
                                 <content styleCode="bold">(inotersen)</content> injection
											<br/>for subcutaneous use 
											<br/>
                                 <br/>
                                 <content styleCode="bold">Instructions For Use</content>
                                 <br/>
                                 <br/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Introduction</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before using your TEGSEDI prefilled syringe, your healthcare provider should show you or your caregiver how to use it the right way. If you or your caregiver have any questions, ask your healthcare provider.</content>
                              </paragraph>
                              <br/>
                              <paragraph>
                                 <content styleCode="bold">Read this Instructions for Use before you start using your TEGSEDI prefilled syringe and each time you get a refill.</content> There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Guide to parts</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM006"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Important information</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store TEGSEDI in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C) in the original container.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> freeze.</item>
                                 <item>TEGSEDI prefilled syringes can also be kept at room temperature that is no higher than 86Â°F (30Â°C) in the original container for up to 6 weeks.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> let TEGSEDI reach temperatures above 86Â°F (30Â°C).</item>
                                 <item>If you do not use TEGSEDI kept at room temperature within the 6 weeks, throw it away. </item>
                                 <item>Protect from light.</item>
                                 <item>
                                    <content styleCode="bold">Keep TEGSEDI and all medicines out of reach of children.</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Each TEGSEDI prefilled syringe contains 1 dose of TEGSEDI and is for 1-time use only.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Warnings</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> remove needle cap until you have reached <content styleCode="bold">Step 6</content> of the <content styleCode="bold">Injection</content> phase of these instructions and are ready to inject TEGSEDI</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> share your syringe with another person or re-use your syringe</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use if dropped onto a hard surface or damaged</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> shake or freeze the prefilled syringe</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use if the expiration date on the side of the syringe body has passed</item>
                              </list>
                              <paragraph>If any of the above happens, throw away the prefilled syringe in a puncture-resistant (sharps) container and use a new prefilled syringe.</paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Preparation</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 1. Gather supplies</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule" align="center">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM007"/>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>1 TEGSEDI prefilled syringe from the refrigerator</item>
                                 <item>1 Alcohol wipe (not supplied)</item>
                                 <item>1 Gauze pad or cotton ball (not supplied)</item>
                                 <item>1 Puncture-resistant (sharps) container (not supplied)</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> perform the injection without all the supplies listed.</paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 2. Prepare to use your TEGSEDI prefilled syringe</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Remove the TEGSEDI tray from the carton and check the expiration date. <content styleCode="bold">Do not</content> use if the expiration date has passed.</item>
                                 <item>Let TEGSEDI warm up at room temperature 68Â°F to 77Â°F (20Â°C to 25Â°C) for 30 minutes before giving the injection.
												<list listType="unordered" styleCode="Circle">
                                       <item>
                                          <content styleCode="bold">Do not</content> warm the syringe in any other way. For example, do not warm in a microwave or hot water, or near other heat sources.</item>
                                    </list>
                                 </item>
                                 <item>Remove the syringe from the tray by holding onto the syringe body.
												<list listType="unordered" styleCode="Circle">
                                       <item>
                                          <content styleCode="bold">Do not</content> move the plunger</item>
                                       <item>
                                          <content styleCode="bold">Do not</content> remove the syringe from the tray by holding onto the needle cap or plunger.</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                           <td styleCode="Toprule Botrule Rrule" align="center">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM008"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 3. Check medicine in the syringe</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM009"/>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Look in the inspection area to check that the TEGSEDI solution is clear and colorless or pale yellow in color. It is normal to see air bubbles in the solution. You do not need to do anything about it.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use if the solution looks cloudy, discolored, or has particles. Throw the prefilled syringe away in a puncture resistant (sharps) container, and use a new prefilled syringe.</item>
                              </list>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 4. Choose the injection site</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM010"/>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Choose an injection site on your abdomen or the front of your thigh.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into the same site each time.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into the 2 inch area around the belly-button (naval).</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject where skin is bruised, tender, red, or hard.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into areas of the skin with scars or tattoos.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject through clothing.</item>
                              </list>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 5. Clean the injection site</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM011"/>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Wash your hands with soap and water.</item>
                                 <item>Clean the injection site with an alcohol wipe in a circular motion. Let the skin air dry.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the area again before injecting.</item>
                              </list>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Injection</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 6. Remove the needle cap</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM012"/>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Hold the syringe by the body, with the needle facing away from you. </item>
                                 <item>Remove needle cap by pulling it straight off. Do not to twist it off. </item>
                                 <item>You may see a drop of liquid at the end of the needle. This is normal. </item>
                                 <item>Keep your hands away from the plunger to avoid pushing the plunger before you are ready to inject. </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> remove the needle cap until right before you inject. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> pull the cap off while holding the syringe by the plunger. Always hold by the body of the syringe. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> let the needle touch any surface.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> remove any air bubbles from the syringe. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> put the needle cap back onto the syringe.</paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 7. Insert the needle</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM013"/>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Hold the syringe in 1 hand.</item>
                                 <item>Hold the skin around at the injection site as your healthcare provider has instructed you. You should either gently pinch the skin at the injection site or give the injection without pinching the skin.</item>
                                 <item>Slowly insert the entire needle into the chosen injection site at a 90Â° angle until fully inserted.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> hold the syringe by the plunger or push against the plunger to insert the needle.</paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 8. Start the injection</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM014"/>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Slowly and firmly push the plunger all the way down until the medicine is injected. Make sure the needle stays fully inserted in the injection site while you are injecting the medicine. </item>
                                 <item>It is important to fully push the plunger all the way down. </item>
                                 <item>Your syringe may make a click sound as you push the plunger down. This is normal. This <content styleCode="bold">does not</content> mean that the injection is finished. </item>
                                 <item>The plunger can feel stiffer towards the end of the injection. You may need to press a little harder on the plunger to make sure you have pushed it as far as it will go. </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> let go of the plunger. </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 9. Push the plunger down</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM015"/>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Push firmly on the plunger at the end of the injection. Hold the plunger fully down and wait for <content styleCode="bold">5 seconds</content>. If you let go of the plunger too quickly, you may lose some of the medicine. </item>
                                 <item>The plunger will start to lift automatically which means that the plunger has been pushed fully down.</item>
                                 <item>Press down again if the plunger does not start to lift automatically.</item>
                              </list>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 10. Complete the injection</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM016"/>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Slowly lift up on the plunger and let the safety spring push the plunger up automatically. </item>
                                 <item>The needle should now be retracted safely inside the syringe, and the safety mechanism spring visible on the outside of the plunger. </item>
                                 <item>When the plunger comes to a stop, your injection is complete. </item>
                                 <item>If the plunger does not rise up automatically when you release the pressure, it means the safety spring did not activate and you should push the plunger again but harder. </item>
                                 <item>Throw away the cap and syringe into the puncture-resistant (sharps) container right away (See section - â<linkHtml href="#dispose">Dispose of the used syringe</linkHtml>â). </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> pull the plunger up by hand. Lift the whole syringe straight up. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> try to replace the cap on the retracted needle. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> rub the injection site.</paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Disposal and care</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph ID="dispose">
                                 <content styleCode="bold">Dispose of the used syringe</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM017"/>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Put the used TEGSEDI prefilled syringe in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) the TEGSEDI prefilled syringe in your household trash. </item>
                                 <item>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is: </item>
                              </list>
                              <list listType="unordered">
                                 <item>
                                    <caption>â</caption> made of heavy-duty plastic,</item>
                                 <item>
                                    <caption>â</caption> can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</item>
                                 <item>
                                    <caption>â</caption> upright and stable during use,</item>
                                 <item>
                                    <caption>â</caption> leak-resistant, and</item>
                                 <item>
                                    <caption>â</caption> properly labelled to warn of hazardous waste inside the container.</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about sharps disposal, and for specific information about safe sharps disposal in the state that you live in, go to the FDAâs website at: </item>
                              </list>
                              <paragraph>
                                 <linkHtml href="http://www.fda.gov/safesharpsdisposal">http://www.fda.gov/safesharpsdisposal</linkHtml>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
               </text>
               <effectiveTime value="20181015"/>
               <component>
                  <observationMedia ID="MM006">
                     <text>Instructions for Use - Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM007">
                     <text>Instructions for Use - Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM008">
                     <text>Instructions for Use - Figure 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM009">
                     <text>Instructions for Use - Figure 4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM010">
                     <text>Instructions for Use - Figure 5</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM011">
                     <text>Instructions for Use - Figure 6</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM012">
                     <text>Instructions for Use - Figure 7</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM013">
                     <text>Instructions for Use - Figure 8</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM014">
                     <text>Instructions for Use - Figure 9</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM015">
                     <text>Instructions for Use - Figure 10</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM016">
                     <text>Instructions for Use - Figure 11</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM017">
                     <text>Instructions for Use - Figure 12</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="81c2364f-b76b-46c2-9af6-74bb1c5d3aca"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title mediaType="text/x-hl7-title+xml">PRINCIPAL DISPLAY PANEL - NDC: 72126-007-02 - Syringe Label</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM018"/>
                  </paragraph>
                  <br/>
                  <br/>
               </text>
               <effectiveTime value="20181015"/>
               <component>
                  <observationMedia ID="MM018">
                     <text>Syringe Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="4b1c00d8-690f-4568-bee9-6603dd5c4c7a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title mediaType="text/x-hl7-title+xml">PRINCIPAL DISPLAY PANEL - NDC: 72126-007-02 - 1-count Tray Label</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM019"/>
                  </paragraph>
                  <br/>
                  <br/>
               </text>
               <effectiveTime value="20210813"/>
               <component>
                  <observationMedia ID="MM019">
                     <text>1-count Tray Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="5311d259-6877-4cc5-8185-f256f8aa9ec0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title mediaType="text/x-hl7-title+xml">PRINCIPAL DISPLAY PANEL - NDC: 72126-007-01 - 4-count Carton Label</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM020"/>
                  </paragraph>
                  <br/>
                  <br/>
               </text>
               <effectiveTime value="20210813"/>
               <component>
                  <observationMedia ID="MM020">
                     <text>4-count Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="inotersen-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>